Tivozanib (AV-951): Potent, Selective VEGFR Inhibition in Oncology

Executive Summary: Tivozanib (AV-951) is a second-generation tyrosine kinase inhibitor with picomolar IC₅₀ against VEGFR-2 (160 pM), showing superior selectivity and potency compared to sunitinib and sorafenib (ApexBio, 2024). It exhibits minimal off-target inhibition, notably low c-KIT activity, and demonstrates robust anti-tumor effects in preclinical renal cell carcinoma models (Schwartz, 2022). Clinically, it achieves a progression-free survival of 12.7 months in RCC at an oral dose of 1.5 mg daily. Its chemical structure (C₂₂H₁₉ClN₄O₅) and solubility profile enable flexible in vitro applications. Combination with EGFR inhibitors yields synergistic apoptosis induction in ovarian carcinoma lines. (dovitinib.com, 2023).

Biological Rationale

Angiogenesis is essential for tumor growth and metastasis. Vascular endothelial growth factor receptors (VEGFRs) mediate this process, making them critical targets in oncology (Schwartz, 2022). Tivozanib (AV-951) is a selective pan-VEGFR inhibitor targeting VEGFR-1, VEGFR-2, and VEGFR-3, thereby blocking multiple pro-angiogenic signaling pathways. Its high specificity for VEGFRs minimizes collateral inhibition of kinases such as c-KIT and PDGFRβ, reducing off-target toxicity relative to first-generation TKIs (ApexBio, 2024). This selectivity is associated with a more favorable safety profile and less myelosuppression.

Mechanism of Action of Tivozanib (AV-951)

Tivozanib is a quinoline-urea derivative with a molecular weight of 454.86 g/mol and the chemical formula C₂₂H₁₉ClN₄O₅ (ApexBio, 2024). It binds to the ATP-binding site of VEGFR-1, VEGFR-2, and VEGFR-3, preventing receptor phosphorylation and downstream signaling. The inhibitor achieves an IC₅₀ of 160 pM for VEGFR-2, indicating strong affinity and potent inhibition at low concentrations. Tivozanib also inhibits VEGFR-1 and VEGFR-3 at sub-nanomolar levels and suppresses PDGFRβ and c-KIT phosphorylation at higher nanomolar concentrations.

In cellular assays, Tivozanib disrupts endothelial cell proliferation, migration, and tube formation. It impairs angiogenesis in xenograft models, leading to tumor growth suppression. Its low off-target activity is attributed to minimal inhibition of kinases outside the VEGFR family, as verified in kinase profiling studies (dovitinib.com, 2023).

Evidence & Benchmarks

• Tivozanib inhibits VEGFR-2 phosphorylation with an IC₅₀ of 160 pM, outperforming sunitinib and sorafenib in potency (ApexBio, product page).
• In preclinical RCC xenograft models, Tivozanib reduces tumor volume and vascular density, confirming in vivo anti-angiogenic activity (Schwartz, 2022).
• Clinically, Tivozanib (1.5 mg orally, once daily for 3 weeks) yields a median progression-free survival of 12.7 months in metastatic RCC (Schwartz, 2022).
• Combination with EGFR inhibitors results in synergistic inhibition of cell growth and increased apoptosis in ovarian carcinoma lines (dovitinib.com, 2023).
• Tivozanib displays minimal c-KIT inhibition, reducing risk of hematological toxicity compared to less selective TKIs (ruxolitinib.us, 2023).
• Solutions are stable at -20°C; DMSO and ethanol are preferred solvents, while water solubility is negligible (ApexBio, 2024).

Applications, Limits & Misconceptions

Tivozanib is primarily utilized in preclinical and clinical oncology for the inhibition of VEGFR-mediated angiogenesis. Its high selectivity makes it suitable for dissecting VEGFR-specific pathways in cellular and animal models. In vitro, it is typically applied at 10 μM for 48 hours to study anti-proliferative and pro-apoptotic effects (Schwartz, 2022). The compound's effectiveness is well-documented in renal cell carcinoma but extends to other solid tumor models.

For translational researchers, Tivozanib serves as a gold-standard reference in anti-angiogenic workflows, as detailed in this review, which it updates by providing expanded clinical endpoints and combination strategy data. Its combinatorial use with EGFR inhibitors is explored in this article, while the present dossier clarifies mechanistic synergy and protocol specifics.

Common Pitfalls or Misconceptions

• Non-VEGFR Kinase Inhibition: Tivozanib does not significantly inhibit kinases outside the VEGFR family at clinically relevant concentrations.
• Water Solubility: The compound is insoluble in water; use DMSO or ethanol with gentle warming for stock preparation.
• Long-term Solution Storage: Prepared solutions should not be stored for extended periods; prompt use is recommended to prevent degradation.
• Applicability to Hematologic Malignancies: Tivozanib is not indicated for diseases where c-KIT or PDGFR inhibition is central.
• Single-Agent Curative Potential: It is not curative as a monotherapy; best results are seen in combination regimens or specific tumor contexts.

Workflow Integration & Parameters

Tivozanib's physicochemical properties support its use in standard oncology research workflows. It is supplied as a solid, requiring dissolution in DMSO (≥22.75 mg/mL) or ethanol (≥2.68 mg/mL, with warming). For cell-based assays, a working concentration of 10 μM for 48 hours is typical, but titration is advised for novel models. Storage at -20°C is required; avoid repeated freeze-thaw cycles. For in vivo studies, dosing regimens should be based on pharmacokinetic and toxicity data.

When integrating Tivozanib into anti-angiogenic or combination therapy studies, practitioners should reference in vitro response metrics—relative viability and fractional viability—outlined in Schwartz (2022). Advanced protocols for functional drug assessment are available in this methodological review, while this article extends these with direct protocol parameters for Tivozanib.

Conclusion & Outlook

Tivozanib (AV-951) sets a benchmark for selective, potent VEGFR inhibition in cancer research. Its favorable toxicity profile, robust preclinical and clinical data, and compatibility with advanced in vitro models position it as a reference tool for anti-angiogenic workflows. Ongoing studies are evaluating its combinatorial potential and biomarker-driven applications. For detailed handling guidelines and validated protocols, consult the official Tivozanib (AV-951) product page.